Objectives: 1. Discuss newer toxins emerged into the clinical scene.
2. Differentiate these newer toxins and show the clinical evidence that has entered into the public domain with respect to these toxins.
Introduction: Botulinum toxin A transformed the aesthetic and cosmetic arena into heights that no one saw coming when the first toxin was approved many years ago.
Results: Newer toxins have emerged into the clinical scene and this presentation will differentiate these newer toxins and show the clinical evidence that has entered into the public domain with respect to these toxins.
Conclusion: In addition, several newer toxins are in clinical trials at this time, and preliminary, public domain data will also be presented. It is an exciting time still for toxins for cosmetic use and we will focus on how some of these newer toxins may make a difference for our patients.
利益冲突声明
您有否接受任何资金来支持研究这个主题?
是
请注明名称(个人,公司,学会等等): Allergan, Galderma, Merz Aesthetics, Revance, Croma
您是否接受过关于这项研究的任何酬金或其他报酬?
是
请注明名称(个人,公司,学会等等): Allergan, Galderma, Merz Aesthetics, Revance, Croma
你是否和任何与您的研究所涉及的药物,材料或工具有密切联系的实体存在财务关系?
否
你是否拥有或者您已经为您此研究中的工具,药物或材料申请任何专利?
否
这项工作的完成感谢以下机构的支持: Allergan, Galderma, Merz Aesthetics, Revance, Croma